• Vaccine Name: Adenovirus Type 3, 7, and 55 Vaccine rAdMHE3-55
• Target Pathogen: Adenovirus
• Target Disease: Respiratory infection
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: HAdV3 hexon protein, HAdV7 hexon protein, HAdV55 hexon protein (Liu et al., 2018)
• Immunization Route: Intramuscular injection (i.m.)
• Description: A trivalent recombinant vector adenovirus vaccine composed of L3 epitopes from HAdV3, HAdV7, and HadV55. (Liu et al., 2018)

Mouse Response

• Vaccination Protocol: Female BALB/c mice were divided into two groups: animals in group vaccinated received rAdMHE3-h55 vaccination, whereas animals in group unvaccinated were only infected with viruses without vaccination. Group vaccinated was further subdivided into the vaccination-challenge group and vaccination-unchallenged group, the latter was served as a control. Mice in group vaccinated were first vaccinated intramuscularly four times with 1X 10^10 genome copies of recombinant virus rAdMHE3-h55at 2-week intervals. (Liu et al., 2018)
• Immune Response: To verify the immunizing potential of the recombinant adenovirus rAdMHE3-h55, we immunized BALB/c mice with three doses of 5 X 10^9 VPs of rAdMHE3-h55. Sera were collected from the mice after the third immunization. Purified adenoviruses of HAdV-55, rAdMHE3, or rAdMHE3-h55 were subjected to western blot analyses with the mouse antisera. For all three adenoviruses, a hexon protein-like band of approximately 120 kDa were detected by anti-rAdMHE3-h55. ELISAs were used to further analyze the antisera from mice immunized with rAdMHE3-h55. The results showed that the mouseanti-rAdMHE3-h55 gave strong responses against HAdV-3, HAdV-7, HAdV-55 and rAdMHE3-h55. These findings confirmed that the recombinant adenovirus rAdMHE3-h55 was able to induce an immune response in mice and the antibodies possessed different neutralizing capabilities against HAdV-3, HAdV-7, and HAdV-55. (Liu et al., 2018)
• Challenge Protocol: Two weeks after the fourth vaccination, mice in the vaccination-challenge group and unvaccinated group, with five or eight mice per time-point, were inoculated intranasally with 50 lL (about 2X 10^11 genome copies) of live HAdV-3, HAdV-7H, or AdV-55. Same number of naïve mice at each time point was served as negative control. Mice were euthanized on post-challenge day 1, 3, or 5.(Liu et al., 2018)
• Efficacy: In order to verify the protective effect of rAdMHE3-h55 vaccination, the respiratory system of the infected mice was examined because this was the target site of the HAdV infection. On post-challenge day 1, 3, or 5, mice were euthanized and their lung tissues were collected. Replication of HAdV-3, HAdV-7 and HAdV-55 in the lung tissues was detected by Q-PCR. There were statistically significant differences in the genome copies between vaccination-challenge group and un-vaccination group by day 5: HAdv-3 (p < 0.01, Mann- Whitney test), HAdV-7 (p < 0.05, Mann-Whitney test), HAdV-55 (p < 0.05, Mann-Whitney test). These data indicated that immunization of BALB/c mice with the recombinant trivalent virus AdMHE3-h55could protect animals simultaneously from infections byHAdV-3, HAdV-7, or HAdV-55.(Liu et al., 2018)